News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
90,068 Results
Type
Article (6671)
Company Profile (37)
Press Release (83360)
Section
Business (27733)
Career Advice (124)
Deals (3997)
Drug Delivery (31)
Drug Development (14102)
Employer Resources (12)
FDA (2827)
Job Trends (2114)
News (49158)
Policy (6001)
Tag
Academia (423)
Africa (91)
Alabama (11)
Allergies (17)
Alliances (8950)
Alzheimer's disease (220)
Antibody-drug conjugate (ADC) (19)
Approvals (2811)
Artificial intelligence (12)
Asia (7342)
Australia (857)
Bankruptcy (17)
Best Places to Work (1732)
BIOSECURE Act (10)
Biosimilars (55)
Biotechnology (25)
C2C Services and Suppliers (6542)
California (376)
Canada (108)
Cancer (102)
Career advice (108)
Cell therapy (29)
China (52)
Clinical research (10992)
Collaboration (35)
Colorado (11)
COVID-19 (517)
Cystic fibrosis (11)
Data (60)
Diabetes (12)
Diagnostics (503)
Drug pricing (17)
Earnings (9020)
Employer resources (10)
Europe (13413)
Events (11275)
Executive appointments (23)
FDA (2897)
Florida (38)
Funding (19)
Gene therapy (27)
GLP-1 (86)
Government (1284)
Healthcare (1961)
Hotbed/Location (58991)
Idaho (13)
Illinois (19)
Indiana (18)
Infectious disease (521)
Inflammatory bowel disease (36)
Interviews (10)
IPO (1818)
Job creations (387)
Job search strategy (106)
Layoffs (45)
Legal (556)
Liver cancer (10)
Lung cancer (36)
Manufacturing (35)
Maryland (172)
Massachusetts (240)
Medical device (1178)
Medtech (1179)
Mergers & acquisitions (2182)
Metabolic disorders (27)
Minnesota (29)
Neuroscience (239)
New Jersey (193)
New York (102)
NextGen Class of 2024 (698)
Non-profit (347)
North Carolina (123)
Northern California (169)
Obesity (10)
Ohio (21)
Opinion (39)
Peanut (16)
Pennsylvania (82)
People (7774)
Phase I (3585)
Phase II (4590)
Phase III (4031)
Pipeline (34)
Policy (21)
Postmarket research (293)
Preclinical (1401)
Press Release (66)
Rare diseases (24)
Real estate (910)
Regulatory (4471)
Reports (10)
Research institute (388)
Resumes & cover letters (11)
South America (133)
Southern California (172)
Startups (575)
Texas (30)
United States (1553)
Vaccines (117)
Washington State (31)
Date
Today (32)
Last 7 days (115)
Last 30 days (405)
Last 365 days (6956)
2024 (4780)
2023 (6998)
2022 (9175)
2021 (9549)
2020 (8250)
2019 (5899)
2018 (4586)
2017 (5102)
2016 (4663)
2015 (5320)
2014 (3748)
2013 (2911)
2012 (2999)
2011 (3155)
2010 (2581)
90,068 Results for "samsung biologics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Samsung Biologics Reports First Quarter 2024 Financial Results
Samsung Biologics, a global contract development and manufacturing organization, announced financial results for the first quarter of fiscal year 2024.
April 24, 2024
·
4 min read
Deals
Samsung Bio Nabs $1B Manufacturing Contract With Undisclosed US Pharma
Samsung Biologics announced Tuesday it has signed its largest contract ever—a $1.06 billion manufacturing deal with an unnamed pharmaceutical company headquartered in the U.S.
July 2, 2024
·
2 min read
·
Tristan Manalac
Policy
FDA Approves PYZCHIVA® (ustekinumab-ttwe), Samsung Bioepis’ Biosimilar to Stelara
Samsung Bioepis Co., Ltd. announced that the U.S. Food and Drug Administration has approved the Biologics License Application for PYZCHIVA® subcutaneous injection and intravenous infusion as a biosimilar to Stelara.
July 1, 2024
·
10 min read
Press Releases
Samsung Biologics joins the Pharmaceutical Supply Chain Initiative as Supplier Partner
August 6, 2024
·
2 min read
Samsung Biologics awarded Leadership status by CDP for climate action efforts
Samsung Biologics, a global contract development and manufacturing organization, announced that it has received the Leadership status and A- rating from the Carbon Disclosure Project.
February 13, 2024
·
2 min read
Business
Samsung Biologics partners with LegoChem Biosciences for ADC development and manufacturing
Samsung Biologics today announced it has signed a partnership agreement with LegoChem Biosciences (KOSDAQ: 141080), a biotech company pioneering the research and development of antibody-drug conjugate (ADC) programs.
February 7, 2024
·
3 min read
Business
Samsung Biologics Reports Fourth Quarter & Fiscal Year 2023 Financial Results
Samsung Biologics announced robust financial results for the fourth quarter and fiscal year 2023.
January 24, 2024
·
5 min read
Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating
Samsung Biologics, a global contract development and manufacturing organization, announced that the company was awarded the EcoVadis’ Platinum Sustainability Rating, the highest recognition given, for the company’s sustainability management.
January 22, 2024
·
3 min read
FDA
Samsung Bioepis Gets FDA Approval for Biosimilar of J&J’s Stelara
Pyzchiva, developed by Samsung Bioepis, will be commercialized in the U.S. by Sandoz with the license period beginning on Feb. 22, 2025, according to a settlement and licensing agreement with Johnson & Johnson’s Janssen Biotech.
July 1, 2024
·
1 min read
·
Tyler Patchen
Genetown
Samsung Invests in BrickBio to Develop Advanced Molecules and Therapies Using Protein Engineering Technology for Antibody-Drug Conjugates (ADC)
Samsung Life Science Fund, created jointly between Samsung Biologics, Samsung Bioepis, and Samsung C&T, and managed by Samsung Ventures, and BrickBio, Inc. announced Samsung’s investment in BrickBio, a preclinical-stage biopharmaceutical company focused on developing precision biologics using an expanded genetic code.
March 18, 2024
·
3 min read
1 of 9,007
Next
